Elevated Rate Pacing of Cardiac Amyloidosis
Purpose
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
Conditions
- Cardiac Amyloidosis
- Pacemaker
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Adults 18 and older - Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee - Implanted Cardiac Pacemaker (+/- Defibrillator) - Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation - Non-dilated left ventricle by echocardiography - Ability to provide written consent - English Speaking
Exclusion Criteria
- Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony) - Dilated left ventricle
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Supportive Care
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Elevated Pacemaker Rate |
CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction. |
|
Recruiting Locations
University of Minnesota
Minneapolis, Minnesota 55455
Minneapolis, Minnesota 55455
More Details
- Status
- Recruiting
- Sponsor
- University of Minnesota